MedImmune
Top Ten most popular articles on Pharmafile.com this week
February 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease
Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
AstraZeneca to retire MedImmune brand amid restructuring
February 15, 2019Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring
AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D …
AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer
September 25, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …
AZ’s MedImmune signs $200m immuno-oncology partnership with Compugen
April 3, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, MedImmune, compugen, immunotherapy, oncology, pharma
AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …
AZ’s Fasenra approved in Europe as an add-on for severe eosinophilic asthma
January 11, 2018Research and Development AstraZeneca, European Commission, Fasenra, MedImmune, asthma, pharma
AstraZeneca and its biologics R&D unit MedImmune have announced that their drug Fasenra (benralizumab) has received approval from the European …
AstraZeneca’s Fasenra scores US approval in severe asthma
November 15, 2017Research and Development, Sales and Marketing AstraZeneca, Fasenra, MedImmune, asthma
AstraZeneca and MedImmune, the company’s biologics research and development division, have revealed the decision by the FDA to approve Fasenra …
AstraZeneca asthma therapy tralokinumab flops at Phase 3
November 1, 2017Research and Development AstraZeneca, MedImmune, asthma, pharma
AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab …
Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%
September 7, 2017Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab
An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …
AstraZeneca strikes mRNA-based partnership in respiratory disease
August 22, 2017Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Ethris, MedImmune, mrna, pharma, pharmaceuticals
AstraZeneca and MedImmune, the company’s biologics research arm, have forged a five year research partnership with mRNA-based pulmonary disease specialist …
AstraZeneca agrees $250 million licensing agreement with Allergan
October 3, 2016Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease
Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …
Clinical trials initiated for novel immunotherapy combo for ovarian cancer
April 7, 2016Medical Communications, Research and Development MedImmune, cancer research institute, clinical trial, ludwig, ovarian cancer, ventirx
A cross collaboration between industry and not-for-profit organisations will see Ludwig Cancer Research and the Cancer Research Institute partner with …
AZ drug gets orphan status for rare inflammatory disease
March 9, 2016Research and Development AstraZeneca, MEDI-551, MedImmune, orphan drug
AstraZeneca’s biologics R&D arm MedImmune has been granted Orphan Drug Designation by the FDA for its investigational anti-CD19 monoclonal antibody, …
AstraZeneca announces tremelimumab setback in mesothelioma test
March 1, 2016Manufacturing and Production, Research and Development AstraZeneca, Cancer, MedImmune, tremelimumab
AstraZeneca and its global biologics research and development arm, MedImmune, have announced a setback in the result of their Phase …
MedImmune and UCSF team up to research RAI treatments
January 13, 2016Research and Development MedImmune, Precision Medicine, University of California San Francisco, autoimmunity
AstraZeneca’s biologics R&D arm MedImmune and the University of California, San Francisco (UCSF) have announced a new research collaboration focused …
AstraZeneca and MedImmune in oncology research deals
January 12, 2016Manufacturing and Production, Research and Development AstraZeneca, Incyte, MedImmune, Moderna Therapeutics
AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
